REG - GSK PLC - EMA grants PRIME Designation for GSK’227

GSKAnnouncement

16/12/2024 07:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241216:nRSP1068Qa&default-theme=true

RNS Number : 1068Q  GSK PLC  16 December 2024

Issued: 16 December 2024, London UK

 

GSK's B7-H3-targeted antibody-drug conjugate, GSK'227, receives EMA Priority
Medicines (PRIME) Designation in relapsed extensive-stage small-cell lung
cancer

 

·   Regulatory designation based on promising preliminary clinical data

·   PRIME Designation granted to medicines with potential to address
significant unmet medical needs

·   Extensive-stage small-cell lung cancer is associated with high rates of
relapse, few treatment options and poor prognosis

 

GSK plc (LSE/NYSE: GSK) announced today that the European Medicines Agency
(EMA) has granted Priority Medicines (PRIME) Designation for GSK5764227
(GSK'227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated
for the treatment of patients with relapsed extensive-stage small-cell lung
cancer (ES-SCLC). The PRIME Designation supports the development of medicines
with potential to offer a major therapeutic advantage for patients. 1 
(#_edn1) This is the second regulatory designation for GSK'227, following the
US Food and Drug Administration's decision to grant Breakthrough Therapy
Designation in August 2024 2  (#_edn2) .

 

Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK,
said: "This PRIME Designation is an important step forward as we seek to
accelerate development of GSK'227 in extensive-stage small-cell lung cancer
and other tumour types with limited treatments. Our investigational
B7-H3-targeted ADC is a key component of our broader ADC programme."

 

The EMA's PRIME Designation is supported by preliminary clinical data from the
ARTEMIS-001 study. This is an ongoing phase I open-label, multi-centre trial
of more than 200 patients evaluating the safety, tolerability, and preliminary
anti-tumour activity in locally advanced or metastatic solid tumours,
including relapsed ES-SCLC, conducted by Hansoh Pharma. The efficacy and
safety results from this trial were presented at the 2024 World Conference on
Lung Cancer earlier this year. GSK recently began a global phase I trial to
support a registrational pathway for GSK'227.

 

Lung cancer is a leading cause of cancer-related morbidity and mortality
worldwide. 3  (#_edn3) In Europe, there were an estimated 484,554 new cases
and 375,784 deaths from lung cancer in 2022. 4  (#_edn4) SCLC represents
10-15% of all lung cancer cases and is among the deadliest subtypes. 5 
(#_edn5) (, 6  (#_edn6) ) ES-SCLC constitutes 60% to 85% of all SCLC cases at
diagnosis and is characterised by tumours that have spread beyond the
lungs. 7  (#_edn7) Platinum resistant or refractory patients typically have
very poor outcomes, with median overall survival of less than six months. 8 
(#_edn8) (,  9  (#_edn9) )

 

Earlier this year, GSK acquired exclusive worldwide rights (excluding China's
mainland, Hong Kong, Macau, and Taiwan) from Hansoh to progress clinical
development and commercialisation of GSK'227. 10  (#_edn10)

 

About GSK'227

GSK'227, also known as HS-20093, is a novel investigational B7-H3-targeted ADC
composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to
a topoisomerase inhibitor (TOPOi) payload. HS-20093 is being developed by
Hansoh Pharma for the treatment of lung cancer, sarcoma, head and neck cancers
and other solid tumours in multiple phase I, II and III clinical trials in
China. GSK's global phase I trial for GSK'227 began in August 2024.

 

GSK in oncology

Oncology is an emerging therapeutic area for GSK where we are committed to
maximising patient survival with a current focus on haematologic malignancies,
gynaecologic cancers, and other solid tumours through breakthroughs in
immuno-oncology and tumour-cell targeting therapies.

 

About GSK

GSK is a global biopharma company with a purpose to unite science, technology,
and talent to get ahead of disease together. Find out more at gsk.com.

 

 GSK enquiries
 Media:               Tim Foley                                 +44 (0) 20 8047 5502  (London)
                      Simon Moore / Dan Smith / Sarah Clements  +44 (0) 20 8047 5502  (London)
                      Kathleen Quinn                            +1 202 603 5003       (Washington DC)
                      Lyndsay Meyer                             +1 202 302 4595       (Washington DC)

 Investor Relations:  Annabel Brownrigg-Gleeson                 +44 (0) 7901 101944   (London)
                      James Dodwell                             +44 (0) 20 8047 2406  (London)
                      Mick Readey                               +44 (0) 7990 339653   (London)
                      Camilla Campbell                          +44 (0) 7803 050238   (London)
                      Steph Mountifield                         +44 (0) 7796 707505   (London)
                      Jeff McLaughlin                           +1 215 751 7002       (Philadelphia)
                      Frannie DeFranco                          +1 215 751 4855       (Philadelphia)

 

Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to risks and
uncertainties that may cause actual results to differ materially from those
projected. Such factors include, but are not limited to, those described under
Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and
GSK's Q3 Results for 2024.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

79 New Oxford Street

London

WC1A 1DG

 

 

(#_ednref1) References

 1  European Medicine Agency. PRIME - Priority Medicines factsheet. Available
at:
https://www.ema.europa.eu/en/documents/leaflet/prime-paving-way-promising-medicines-patients-factsheet_en.pdf
(https://www.ema.europa.eu/en/documents/leaflet/prime-paving-way-promising-medicines-patients-factsheet_en.pdf)

 2  (#_ednref2) GSK. GSK receives US FDA Breakthrough Therapy Designation for
its B7-H3-targeted antibody-drug conjugate in relapsed or refractory
extensive-stage small-cell lung cancer
https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-fda-breakthrough-therapy-designation/

 3  (#_ednref3) Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of
lung cancer: current status and future

trends. Nat Rev Clin Oncol. 2023;20(9):624-639.

 4  (#_ednref4) Bray F, Laversanne M, Sung H, et al. Global cancer statistics
2022: GLOBOCAN estimates of incidence

and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.
2024;74(3):229-263.

 5  (#_ednref5) Rudin CM, Brambilla E, Faivre-Finn C, et al. Small-cell lung
cancer. Nat Rev Dis Primers. 2021;7(1):3.

 6  (#_ednref6) Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we
know, what we need to know and the

path forward. Nat Rev Cancer. 2017 Dec;17(12):725-737. Doi:
10.1038/nrc.2017.87. Epub 2017 Oct

27. Erratum in: Nat Rev Cancer. 2017;17(12):765.

 7  (#_ednref7) Porte M, Vaudron A, Crequit P, Vaugier L, Chatellier T,
Fronteau C, Raimbourg J, Goronflot T, Bennouna J, Pons-Tostivint E. A
Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line
Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC)
Patients. Clin Lung Cancer. 2024 Mar;25(2):e101-e111.e2. doi:
10.1016/j.cllc.2023.11.009. Epub 2023 Nov 23. PMID: 38072729.

 8  (#_ednref8) Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA,
Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A,
Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R,
Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla
SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J,
Paz-Ares L. Lurbinectedin as second-line treatment for patients with
small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet
Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020
Mar 27. Erratum in: Lancet Oncol. 2020 Dec;21(12):e553. doi:
10.1016/S1470-2045(20)30676-8. PMID: 32224306.

 9  (#_ednref9) Topotecan USP. Available at:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022453s002lbl.pdf
(https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022453s002lbl.pdf)
. Accessed 13 Nov 2024

 10  (#_ednref10) GSK. GSK enters exclusive license agreement with Hansoh for
HS-2009. Available at:
https://www.gsk.com/en-gb/media/press-releases/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093/
(https://www.gsk.com/en-gb/media/press-releases/gsk-enters-exclusive-license-agreement-with-hansoh-for-hs-20093/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCGPGRCPUPCGQW